Re: And even more new drugs

[Guest guest]

Hi Tracey,

I am also impressed. My observation is that medication for CML was a done

deal with Imatinib. Let's face it. 85% of those diagnosed with CML achieve a

long lasting remission. For the remaining 15%, Disatinib and Nilotinib take

care of at least 10% leaving less than 5% for which there are now a half a

dozen new drugs that work.

For most of us, we are waiting for a cure. I am one who believes (call me a

religious zealot) that one will come within 20 years and it will come from

the researchers in the universities and the hospitals. There is no money in

it for the pharmaceuticals to develop a cure. However, there is a ton of

money available if they can replace Imatinib with their own drug.

And don't discount transplants. There have been tremendous strides being

made in that area.

Zavie

Zavie (age 69)

67 Shoreham Avenue

Ottawa, Canada, K2G 3X3

dxd AUG/99

INF OCT/99 to FEB/00, CHF

No meds FEB/00 to JAN/01

Gleevec since MAR/27/01 (400 mg)

CCR SEP/01. #102 in Zero Club

2.8 log reduction Sep/05

3.0 log reduction Jan/06

2.9 log reduction Feb/07

3.2 log reduction Jun/07

e-mail: zmiller@...

Tel: 613-726-1117

Fax: 309-296-0807

Cell: 613-202-0204

ID: zaviem

_____

From: [mailto: ] On Behalf Of Tracey

Sent: August 23, 2007 10:12 PM

Subject: [ ] And even more new drugs

I just can't get over how many drugs are being looked at these days.

Here are a few more that I left out of my last post:

1)Clofarabine is being trialled for people in blast crisis

2)Velcade (also known as Bortezomib) is a proteasome inhibitor that

is being investigated in some centers for CML.

3)Fludarabine has been used in CLL but is also being trialled for

blast phase CML.

4)LBH589 is a histone deacetylase inhibitor being trialled for some

CML patients who have failled other therapies.

5)XL228 is another drug being used for the T315I mutation

6)CP-4055 is a drug that is simillar to an older drug that used to be

used with Interferon called Cytarabine (Ara-C).

It kind of makes me wonder where they're going to get enough people

to sign up for all these trials. It almost seems like there are more

drugs than there are patients to try them.

Tracey

[Guest guest]

> It kind of makes me wonder where they're going to get enough people

> to sign up for all these trials. It almost seems like there are more

> drugs than there are patients to try them.

>

> Tracey

>

Nice summary.

Dr. Talpaz at Univ of Michigan often makes a joke during his

presentations that reflects exactly this sentiment.

Still plenty of understanding of the biology of the CML cell left to

fighure out. Nice to have so much to work with.

Just as an FYI, I've been told that the Onconova drug ON102380 did not

exhibit a favorable risk/benefit profile in animal testing and further

development was dropped.

All the Farensyl Transferase Inhibitors have been mostly disappointing

in leukemia trials so far.

[Guest guest]

There is no money in

> it for the pharmaceuticals to develop a cure. However, there is a

ton of

> money available if they can replace Imatinib with their own drug.

>

> And don't discount transplants. There have been tremendous strides

being

> made in that area.

>

> Zavie

>

>

Your right about transplants and immunotherapy.

In truth, there is actually a great deal of collaboration between

researchers at Pharmaceutical companies and those at Universities.

The understanding of CML biology is being advanced every year mainly

by academic labs using drugs discovered in pharma labs.

I have been told that Novartis is providing funding for various

vaccine trials that if proved out would likely result in a decrease

in Gleevec sales.

Also, with the patent laws no pharmaceutical company can hold

exclusive rights to a drug for too long. I believe their mind set is

that eventually even a super money making drug ultimately loses

patent rights and becomes a generic so they should enjoy it while

they can.

[Guest guest]

Well said, Zavie, well said. And who cares if you are a religious zealot,

there is a certain amount of faith in our walk with CML.

Sincerely,

Matt

Zero Club #1078

ville, Florida

Dx January of 2005

Gleevec since March of 2005

Treated at MD

Father of 3

In a message dated 8/23/2007 9:51:28 P.M. Eastern Standard Time,

zmiller@... writes:

Hi Tracey,

I am also impressed. My observation is that medication for CML was a done

deal with Imatinib. Let's face it. 85% of those diagnosed with CML achieve a

long lasting remission. For the remaining 15%, Disatinib and Nilotinib take

care of at least 10% leaving less than 5% for which there are now a half a

dozen new drugs that work.

For most of us, we are waiting for a cure. I am one who believes (call me a

religious zealot) that one will come within 20 years and it will come from

the researchers in the universities and the hospitals. There is no money in

it for the pharmaceuticals to develop a cure. However, there is a ton of

money available if they can replace Imatinib with their own drug.

And don't discount transplants. There have been tremendous strides being

made in that area.

Zavie

Zavie (age 69)

67 Shoreham Avenue

Ottawa, Canada, K2G 3X3

dxd AUG/99

INF OCT/99 to FEB/00, CHF

No meds FEB/00 to JAN/01

Gleevec since MAR/27/01 (400 mg)

CCR SEP/01. #102 in Zero Club

2.8 log reduction Sep/05

3.0 log reduction Jan/06

2.9 log reduction Feb/07

3.2 log reduction Jun/07

e-mail: _zmiller@..._ (mailto:zmiller@...)

Tel: 613-726-1117

Fax: 309-296-0807

Cell: 613-202-0204

ID: zaviem

_____

From: _@..._ (mailto: )

[mailto:_@..._ (mailto: ) ] On Behalf Of

Tracey

Sent: August 23, 2007 10:12 PM

_@..._ (mailto: )

Subject: [ ] And even more new drugs

I just can't get over how many drugs are being looked at these days.

Here are a few more that I left out of my last post:

1)Clofarabine is being trialled for people in blast crisis

2)Velcade (also known as Bortezomib) is a proteasome inhibitor that

is being investigated in some centers for CML.

3)Fludarabine has been used in CLL but is also being trialled for

blast phase CML.

4)LBH589 is a histone deacetylase inhibitor being trialled for some

CML patients who have failled other therapies.

5)XL228 is another drug being used for the T315I mutation

6)CP-4055 is a drug that is simillar to an older drug that used to be

used with Interferon called Cytarabine (Ara-C).

It kind of makes me wonder where they're going to get enough people

to sign up for all these trials. It almost seems like there are more

drugs than there are patients to try them.

Tracey

[Non-text portions of this message have been removed]

************************************** Get a sneak peek of the all-new AOL at

http://discover.aol.com/memed/aolcom30tour

[Guest guest]

A couple of nice summaries Tracey. Thanks. It helps to see them all

put together in a group listing(s) Especially for people like me who

don't frequent these CML lists on a regular basis. It is also good to

have an overview of what is out there when we speak to our individual

oncs. You have done us all a favour.

Wayne

>

> I just can't get over how many drugs are being looked at these

days.

> Here are a few more that I left out of my last post:

>

> 1)Clofarabine is being trialled for people in blast crisis

>

> 2)Velcade (also known as Bortezomib) is a proteasome inhibitor that

> is being investigated in some centers for CML.

>

> 3)Fludarabine has been used in CLL but is also being trialled for

> blast phase CML.

>

> 4)LBH589 is a histone deacetylase inhibitor being trialled for some

> CML patients who have failled other therapies.

>

> 5)XL228 is another drug being used for the T315I mutation

>

> 6)CP-4055 is a drug that is simillar to an older drug that used to

be

> used with Interferon called Cytarabine (Ara-C).

>

> It kind of makes me wonder where they're going to get enough people

> to sign up for all these trials. It almost seems like there are

more

> drugs than there are patients to try them.

>

> Tracey

>

[Guest guest]

Actually Zavie is also correct about big pharma. If they found a cure

for cancer every major drug company would either go out of business

or be scrambling to get out from under a catastrophic financial hit.

Since we are talking Novartis, I think they have shown a more than

average amount of committment towards their CML patients when you

compare them with other drug companies. Of course if their new drug

for CML is approved; they will have most of the CML market wrapped

up, with the majority of us on gleevec now and then some of the

resistant group going on AMN107 which hopefully will be approved

soon.

As for the patent laws that is a bit of red herring. How long do they

last?? In Canada I believe it is close to.. if not 20 years. Many

drugs are " tweeked " at this point and repackaged to start all over

again as a " new " drug. Losec and Nexium are a good example.

I believe in the free market system that is helping to bring these

new life savers to the market but you come across as a bit of a

cheerleader for the drug companies and I'm not sure what your agenda

is.

Wayne

-- In , " " <timothyfarley16@...> wrote:

> Your right about transplants and immunotherapy.

>

> In truth, there is actually a great deal of collaboration between

> researchers at Pharmaceutical companies and those at Universities.

> The understanding of CML biology is being advanced every year

mainly

> by academic labs using drugs discovered in pharma labs.

>

> I have been told that Novartis is providing funding for various

> vaccine trials that if proved out would likely result in a decrease

> in Gleevec sales.

>

> Also, with the patent laws no pharmaceutical company can hold

> exclusive rights to a drug for too long. I believe their mind set

is

> that eventually even a super money making drug ultimately loses

> patent rights and becomes a generic so they should enjoy it while

> they can.

>